Skip to content
lifestyle.smarttalksuccess.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Zealand Pharma
Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
May 5, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
May 4, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
May 4, 2026
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026
May 4, 2026
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations
May 3, 2026
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830
February 18, 2026
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results
February 12, 2026
←
Previous Page
1
…
4
5
6